Allergy therapies
-
Steve Saviuk, CEO of Valeo Pharma, Discusses Promising Results of COVID-19 Drug Sabizabulin and Revenue Growth in 2023
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO, and…
-
Valeo Pharma’s CEO Steve Saviuk Talks about Record FQ4 & F2022 Revenue Up 274% & 105%, Respectively
In this InvestorIntel interview, Tracy Weslosky talks to Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO,…
-
Record revenues in 2022 of $27.7 million, Valeo Pharma investment in commercial infrastructure starts to pay off
What a difference a year makes. Last year at this time we were heading into wave something or…
-
Steve Saviuk on how Valeo Pharma’s ‘life changing’ products have delivered the strong growth forecasted for 2022
In this InvestorIntel interview, Tracy Weslosky interviews Valeo Pharma Inc.’s (TSX: VPH | OTCQB: VPHIF) Founder, CEO and…
-
Valeo Pharma keeps delivering with a 100% revenue growth forecast in 2022 and more new effective pharmaceuticals
Early in 2022 InvestorIntel updated readers about a company that was growing its revenue at an incredible rate…
-
Steve Saviuk of Valeo Pharma talks about acquiring new therapeutic drugs and record Q3 revenue
In this interview, InvestorIntel Publisher and Editor in Chief Stephen Lautens talks to Valeo Pharma Inc.’s (TSX: VPH…
